Entelexo Analysis
What is Entelexo?
Entelexo develops exosome-based therapeutics targeting autoimmune diseases using a proprietary engineering platform. Their approach addresses the complexities of these diseases by enabling engineered exosomes to communicate with multiple cell types simultaneously. The company aims to create indication-specific treatments that align with the natural complexities of autoimmune conditions.
HQ Country
Irvine, United States
Employees
1-10
Founded
2020
Product Features & Capabilities
- Proprietary engineering platform for exosome therapeutics
- Drug candidates for autoimmune diseases
- Human cell assays for risk mitigation
